Omega Funds — 2026 Investments
3 investments dated 2026 · listed companies and verified rows first · show all
Alveus Therapeutics develops next-generation metabolic and obesity therapies, including its lead asset ALV-100 (in Phase 2) and a preclinical amylin pipeline of peptides, oral small molecules, and novel formats aimed at sustainable weight loss with better tolerability.
BiotechHealthtechLongevityPhiladelphia, US
Raj Kannan(Executive Officer, Director)
BoardIvan Gergel(Director)inJan Van de Bossche(Director)inGarrett Ingram(Director)Gregory Parekh(Director)
Board seatClaudio Nessi· per SEC Form D · $110.7M raise · filed Jan 2026
Co-investorsAndera PartnersAvego BioScience CapitalGlobal BioAccess FundJeito CapitalNew Rhein Healthcare Investors, LLCSeroba Life Sciences+2 more
BiotechCambridge, US
Praveen Tipirneni(Executive Officer, Director)
BoardAaron Royston(Director)Michael Gladstone(Director)inXiaodi Su(Director)
Board seatMichelle Doig· per SEC Form D · $37.5M raise · filed Jan 2026
Co-investorsAtlas VentureBain Capital Life SciencesJanus Henderson InvestorsLAVvenBio Global StrategicvenBio Partners+1 more
Spiro Medical develops an implantable neuromodulation system using targeted spinal nerve stimulation to modulate respiratory function in patients with severe, uncontrolled asthma who have not responded to conventional treatments.
BiotechHealthtechMedical DevicesBelleair Bluffs, US
Rinda Sama(Executive Officer)
BoardBrian Mooney(Director)
Board seatClaudio Nessi· per SEC Form D · $69.1M raise · filed Jan 2026
Co-investorsAndera PartnersSupernova Invest
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.